Standard BioTools Inc.

Informe acción NasdaqGM:SLGC

Capitalización de mercado: US$396.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Standard BioTools Dirección

Dirección controles de criterios 2/4

El CEO de Standard BioTools es Adam Taich, nombrado en Mar 2023, tiene una permanencia de menos de un año. posee directamente un 0.13% de las acciones de la empresa, con un valor de $501.15K. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 4 años, respectivamente.

Información clave

Adam Taich

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEOless than a year
Participación del CEO0.1%
Permanencia media de la dirección2yrs
Promedio de permanencia en la Junta Directiva4yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • Dec 19

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc.'s ( NASDAQ:SLGC ) price-to-sales (or "P/S") ratio of 4.9x may not look like an appealing investment...
Artículo de análisis • Nov 10

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

SomaLogic, Inc. ( NASDAQ:SLGC ) investors will be delighted, with the company turning in some strong numbers with its...
Artículo de análisis • Apr 17

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

SomaLogic, Inc. ( NASDAQ:SLGC ) shareholders are no doubt pleased to see that the share price has bounced 33% in the...
Artículo de análisis • Apr 02

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Today is shaping up negative for SomaLogic, Inc. ( NASDAQ:SLGC ) shareholders, with the analysts delivering a...
Seeking Alpha • Oct 17

SomaLogic appoints former Foundation Medicine chief as executive chair

SomaLogic (NASDAQ:SLGC) said Monday it appointed board member and biotech veteran Troy Cox as executive chair of its board, effective immediately. Chuck Lillis, the company's current chair, continue to serve as a board member. Cox has over 30 years' experience in life sciences and biopharmaceuticals, who'd earlier served as CEO of Foundation Medicine.
Seeking Alpha • Jul 26

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

SomaLogic (NASDAQ:SLGC) to acquire Palamedrix, an innovator in DNA nanotechnology, that provides deep scientific and engineering expertise, miniaturization technology and enhanced ease-of-use capabilities that company intends to leverage as it develops the next generation of the SomaScan Assay. Under the terms of the merger agreement, company will pay at closing $35M, comprising $14M in cash and $21M in company stock. Up to an additional $17.5M may be paid in connection with the achievement of certain future revenue-based milestones.  Transaction expected to close in Q3 and is not expected to contribute to revenue. As part of the transaction, company will obtain the intellectual property covering Palamedrix’s core DNA-based technology platform for the integration of molecular biosensors onto chips.
Artículo de análisis • Jun 06

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 12

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

SomaLogic offers a pioneering platform for the study and engineering of various proteins, which lends itself to a large number of diseases giving the company a large pipeline. The company’s business approach sees them partner with other companies, selling the rights to utilize their platforms in their research which provides revenue while keeping costs low. The company recently announced that it would lend its services to EPIC for a project that aims to analyze and understand cancer development to predict it in the future.
Artículo de análisis • Mar 09

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

Does the March share price for SomaLogic, Inc. ( NASDAQ:SLGC ) reflect what it's really worth? Today, we will estimate...
Artículo de análisis • Dec 28

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 14

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

SomaLogic was founded in 2000 by Larry Gold, who earlier founded NeXstar Pharmaceuticals, which was acquired by Gilead (GILD) for $550M. Institutional holders in the company include Ark Investment Management, Perceptive Advisors, Illumina, Softbank, Redmile Group, etc. The SomaScan Discovery Platform can analyze 7000 proteins in just 55 microL of blood sample, over 3.5x than competition. Current customers include Bristol-Myers Squibb (BMY), Novartis, Stanford, University of Cambridge, Henry Ford Health System, Alkahest, Louisiana State University, etc. This could be a 10x potential investment opportunity in a 10+ years time frame even if it occupies just 10% market share in the global proteomics market.

CEO

Adam Taich (47 yo)

less than a year
Permanencia

Mr. Adam Taich was Executive Vice President of Life Sciences Business Unit at Standard BioTools Inc. (formerly known as SomaLogic, Inc.) since August 2022 until March 28, 2023 and serves as its Interim Chi...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Stephen Williams
Chief Medical Officer15yrsUS$2.55m0.085%
$ 336.3k
Adam Taich
Interim CEOless than a yearsin datos0.13%
$ 501.1k
Pi Zheng
Interim Chief Accounting Officerless than a yearsin datossin datos
Jason Cleveland
Chief Technology Officer3yrssin datossin datos
Nebojsa Janjic
Chief Science Officer15yrssin datossin datos
Ruben Gutierrez
General Counsel2yrssin datos0.059%
$ 232.1k
Alison Roelke
Chief People Officer2yrssin datos0.0091%
$ 36.0k
Shane Bowen
Chief Research & Development Officer1yrsin datossin datos
2.0yrs
Permanencia media
48.5yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de SLGC se considera experimentado (2 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Richard Post
Independent Director4.3yrsUS$202.07k0.030%
$ 120.6k
Craig Mundie
Member of Advisory Boardno datasin datossin datos
Eli Casdin
Independent Director3.1yrsUS$197.57k0.0018%
$ 7.2k
Jason Ryan
Independent Chairmanless than a yearsin datossin datos
Thomas Carey
Independent Directorless than a yearsin datossin datos
Troy Cox
Independent Director2.3yrsUS$2.59m0.042%
$ 164.7k
Anne Marguiles
Independent Director4.3yrsUS$204.70k0.012%
$ 49.2k
Peter Ganz
Member of Medical Advisory Board4yrssin datossin datos
Rosalind Raine
Member of Medical Advisory Board4yrssin datossin datos
Marc Feldmann
Member of Medical Advisory Board4yrssin datossin datos
Michael Blum
Member of Medical Advisory Board4yrssin datossin datos
John Tooke
Member of Medical Advisory Board4yrssin datossin datos
4.0yrs
Permanencia media
62.5yo
Promedio de edad

Junta con experiencia: La junta directiva de SLGC se considera experimentada (4 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2024/01/09 05:28
Precio de las acciones al final del día2024/01/05 00:00
Beneficios2023/09/30
Ingresos anuales2022/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Standard BioTools Inc. está cubierta por 3 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Kyle MiksonCanaccord Genuity
Brandon CouillardJefferies LLC
Daniel BrennanTD Cowen